The intent of the collaboration between the three parties is to jointly conduct further research to discover and develop compounds that target the hepatitis C virus (HCV).
The National Health Research Institutes (NHRI) and Genelabs scientists will jointly work to discover and develop new HCV drug candidates by utilizing Genelabs’ know-how and lead compounds on an existing target and NHRI’s chemistry and drug discovery expertise.
Ronald Griffith, Genelabs’ CSO, said: “The collaboration will increase the level of chemistry and biology research activities on a selected Genelabs project targeting the HCV virus.”